Form SC 13G - Statement of Beneficial Ownership by Certain Investors
2024年8月15日 - 8:23AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
13G
Under
the Securities Exchange Act of 1934
(Amendment
No. )*
Provectus
Biopharmaceuticals, Inc.
(Name
of Issuer)
Common
Stock, $0.001 par value per share
(Title
of Class of Securities)
74373P108
(CUSIP
Number)
Jeffrey
Allen Morris
1729
Triangle Park Dr.
Maryville,
TN 37801
(865)
981-8822
(Name,
address and telephone number of person authorized to receive notices and communications)
August
12, 2024
(Date
of event which requires filing of this statement)
Check
the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐
Rule 13d-1(b)
☒
Rule 13d-1(c)
☐
Rule 13d-1(d)
* |
The
remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject
class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior
cover page. |
The
information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18
of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall
be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 74373P108 | SCHEDULE 13G | Page 2 of 5 Pages |
1 |
NAME
OF REPORTING PERSON |
|
|
|
|
Jeffrey
Allen Morris |
2 |
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
(a)
☐ |
|
|
(b)
☐ |
3 |
SEC
USE ONLY |
|
|
|
4 |
CITIZENSHIP
OR PLACE OF ORGANIZATION |
|
|
|
United
States of America |
NUMBER
OF
SHARES
BENEFICIALLY
OWNED
BY
EACH
REPORTING
PERSON
WITH |
5 |
SOLE
VOTING POWER |
|
|
|
61,100,610
|
6 |
SHARED
VOTING POWER |
|
|
|
0 |
7 |
SOLE
DISPOSITIVE POWER |
|
|
|
61,100,610 |
8 |
SHARED
DISPOSITIVE POWER |
|
|
|
0
|
9 |
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
|
|
|
|
61,100,610
(1) |
10 |
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES |
☐ |
|
|
|
11 |
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (9) |
|
|
|
|
|
11.3%
(2) |
|
12 |
TYPE
OF REPORTING PERSON |
|
|
|
|
|
IN |
|
(1) |
Includes
12,000,000 shares of Common Stock held by the Reporting Person; 6,500,000 shares of Common Stock owned by the Reporting Person through
a retirement plan; and 4,260,061 shares of Series D-1 Convertible Preferred Stock issued though conversion of convertible promissory
notes. The 4,260,061 shares of Series D-1 stock are convertible into 42,600,610 shares of Common Stock. |
(2) |
This
percentage is calculated based on a total of 61,100,610 of Common Stock held upon conversion of the Series D-1 shares, and 540,979,974
shares of the Issuer outstanding. |
CUSIP No. 74373P108 | SCHEDULE 13G | Page 3 of 5 Pages |
Item
1(a) |
Name
of Issuer:
Provectus
Biopharmaceuticals, Inc. (the “Issuer”) |
|
|
Item
1(b) |
Address
of Issuer’s Principal Executive Offices:
800
S. Gay Street
Suite
1610
Knoxville,
TN 37929 |
|
|
Item
2(a) |
Name
of Person Filing:
Jeffrey
Allen Morris (the “Reporting Person”). |
|
|
Item
2(b) |
Address
of Principal Business Office or, if none, Residence:
The
address for the principal business office of the Reporting Person is:
1729
Triangle Park Drive
Maryville,
TN. 37801 |
|
|
Item
2(c) |
Citizenship:
The
Reporting Person is a citizen of the United States. |
|
|
Item
2(d) |
Title
of Class of Securities:
Common
Stock, par value $0.001 per share (“Common Stock”) |
|
|
Item
2(e) |
CUSIP
No.:
74373P108 |
|
|
Item
3. |
If
this Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the Person Filing is: |
|
(a) |
☐ |
Broker
or dealer registered under Section 15 of the Exchange Act; |
|
(b) |
☐ |
Bank
as defined in Section 3(a) (6) of the Exchange Act; |
|
(c) |
☐ |
Insurance
company as defined in Section 3(a) (19) of the Exchange Act; |
|
(d) |
☐ |
Investment
company registered under Section 8 of the Investment Company Act; |
|
(e) |
☐ |
An
investment adviser in accordance with Rule 13d-1(b) (1) (ii) (E); |
|
(f) |
☐ |
An
employee benefit plan or endowment fund in accordance with Rule 13d-1(b) (1) (ii) (F); |
|
(g) |
☐ |
A
parent holding company or control person in accordance with Rule 13d-1(b) (1) (ii) (G); |
|
(h) |
☐ |
A
savings association as defined in Section 3(b) of the Federal Deposit Insurance Act; |
|
(i) |
☐ |
A
church plan that is excluded from the definition of an investment company under Section 3(c) (14) of the Investment Company Act; |
|
(j) |
☐ |
Group,
in accordance with Rule 13d-1(b) (1) (ii) (J). |
CUSIP No. 74373P108 | SCHEDULE 13G | Page 4 of 5 Pages |
As
of August 14, 2024, the Reporting Person had sole voting and dipositive power over 61,100,610 shares of Common Stock. This Includes 12,000,000
shares of Common Stock directly held by the reporting person; 6,500,000 shares of Common Stock owned by the Reporting Person through
a retirement plan; and 4,260,061 shares of Series D-1 Convertible Preferred Stock issued though conversion of convertible promissory
notes. The 4,260,061 shares of Series D-1 stock are convertible into 42,600,610 shares of Common Stock.
The
following sets forth in tabular format the share ownership of the Reporting Person:
|
(a) |
Amount
beneficially owned: 61,100,610 shares of Common Stock |
|
(b) |
Percent
of class: 11.3% |
|
(c) |
Number
of shares as to which such person has: |
|
(i) |
sole
power to vote or to direct the vote: |
|
|
61,100,610
shares |
|
|
|
|
(ii) |
shared
power to vote or to direct the vote: |
|
|
0
shares |
|
|
|
|
(iii) |
sole
power to dispose or to direct the disposition of: |
|
|
61,100,610
shares |
|
|
|
|
(iv) |
shared
power to dispose or to direct the disposition of: |
|
|
0
shares |
Item
5. |
Ownership
of Five Percent or Less of a Class. |
|
|
|
If
this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial
owner of more than five percent of the class of securities, check the following ☐. |
|
|
Item
6. |
Ownership
of More than Five Percent on Behalf of Another Person. |
|
|
|
Not
applicable. |
|
|
Item
7. |
Identification
and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. |
|
|
|
Not
applicable. |
|
|
Item
8. |
Identification
and Classification of Members of the Group. |
|
|
|
Not
applicable. |
|
|
Item
9. |
Notice
of Dissolution of Group. |
|
|
|
Not
applicable. |
By
signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not
held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired
and are not held in connection with or as a participant in any transaction having that purpose or effect.
CUSIP No. 74373P108 | SCHEDULE 13G | Page 5 of 5 Pages |
SIGNATURES
After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete
and correct.
Date:
August 14, 2024 |
|
|
|
|
/s/
Jeffrey Allen Morris |
|
Jeffrey
Allen Morris |
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
過去 株価チャート
から 7 2024 まで 8 2024
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
過去 株価チャート
から 8 2023 まで 8 2024